Medtronic has just received FDA approval for its Hugo surgical robot system in the U.S., positioning it as a potential growth opportunity similar to Intuitive Surgical's da Vinci system. With a P/E of 27 compared to Intuitive Surgical's 64, Medtronic appears undervalued and could see significant upside if Hugo achieves similar adoption rates. The company also offers a 2.9% dividend yield with decades of increases, making it attractive for dividend investors.

Medtronic is positioned as an attractive lifetime hold in the medical device sector, expanding into robotic surgery with FDA approval for its Hugo system. The company offers a compelling valuation (P/E of 16.3), a 48-year dividend increase streak with a 2.9% yield, and is spinning off its diabetes division to focus on faster-growing businesses. Recent Q3 results showed 8.7% revenue growth year-over-year.

The global medical device cleaning market is projected to grow from USD 2.08 billion in 2024 to USD 3.74 billion by 2032, driven by escalating infection prevention requirements, expanding reusable device utilization, and technological advancements in automated reprocessing systems. However, high capital costs, complex regulatory obligations, and workforce training variability pose challenges to uniform adoption across regions.

Anteris Technologies reported 2025 financial results with net operating cash outflows of $77.8 million, driven by increased clinical and manufacturing activities. The company initiated the global PARADIGM Trial for its DurAVR® transcatheter heart valve, received FDA IDE approval, and completed a strategic $320 million capital raise including investment from Medtronic to support commercialization efforts.

The global neuromodulation devices market is projected to grow from USD 7.8 billion in 2024 to USD 16.1 billion by 2032, driven by increasing prevalence of chronic neurological conditions, technological innovations, and supportive regulatory frameworks. North America leads with 55% market share, while Asia-Pacific emerges as the fastest-growing region with over 12% CAGR. Recent FDA approvals include ProlivRx for depression treatment and Medtronic's adaptive deep brain stimulation system for Parkinson's disease.

The global Brain Computer Interface (BCI) market is expected to grow from USD 3.07 billion in 2025 to USD 13.32 billion by 2035, with a CAGR of 15.81%. Growth is driven by advances in neural signal processing, increasing prevalence of neurological diseases, and expanding healthcare applications. Non-invasive BCIs currently dominate with 58.42% market share, while the medical segment accounts for 67.35% of end-use applications. However, high costs and limited accessibility remain significant barriers to market expansion.

Medtronic is highlighted as a recession-resistant healthcare company with a strong dividend track record of 48 consecutive annual raises and a 3% yield. The company operates across four business segments with essential medical products, has posted annual net income for over 60 years, and recently received FDA clearance for its Hugo robotic-assisted surgery system. Despite underperforming the S&P 500 in recent years, the author believes the stock is positioned for future outperformance.

The global tele-monitoring services market is valued at USD 36.59 billion in 2026 and is expected to reach USD 164.55 billion by 2035, growing at an 18.18% CAGR. North America leads the market while Asia Pacific shows the fastest growth. Remote patient monitoring dominates by service type, with wearables and mobile devices driving device segment growth. Key drivers include rising chronic disease prevalence, aging populations, and technological advancements in IoT and AI.

Orchestra BioMed (OBIO) announced its participation in two major institutional investor conferences in March 2026: the TD Cowen 46th Annual Health Care Conference (March 3rd) and the Barclays 28th Annual Global Healthcare Conference (March 11th). Management will conduct fireside chats and one-on-one investor meetings at both events.

The global rigid endoscopes market is projected to grow from USD 7.36 billion in 2025 to USD 11.52 billion by 2033, at a CAGR of 5.84%. Growth is driven by technological advancements in HD and 4K imaging, increasing adoption of minimally invasive procedures across multiple surgical specialties, and the rapid expansion of ambulatory surgery centers. North America leads with 41% market share, while Asia-Pacific is expected to register the highest growth rate at 8.00%.

Medtronic reported Q3 2026 results with sales of $9.02 billion, beating consensus estimates of $8.91 billion, with 8.7% year-over-year growth and 6% organic growth. The company reaffirmed its fiscal 2026 guidance of 5.5% organic revenue growth and adjusted EPS of $5.62-$5.66. Strong performance was driven by the Cardiovascular Portfolio (10.6% organic growth) and Diabetes business (8.3% organic growth). Despite beating earnings expectations, shares fell 2.84% at the time of publication.

The global hemostasis products market is projected to grow from USD 1.94 billion in 2025 to USD 3.28 billion by 2035, at a CAGR of 5.41%. Growth is driven by increasing surgical procedures, trauma cases, and demand for advanced bleeding control technologies. However, high product costs and low reimbursement in developing nations pose challenges. Topical hemostats and sponge/pad forms dominate the market, while flowable hemostats and matrix/gel forms show fastest growth. North America leads with 41.62% market share, while Asia-Pacific is the fastest-growing region.